Talkiatry stock
Private-market facts for current and former Talkiatry employees researching their stock.
Overview
In-network psychiatric practice providing virtual and in-person psychiatric care, including medication management and therapy, covered by major insurance plans.
Talkiatry outlook
For employees evaluating Talkiatry equity, a 1x base multiple suggests the stock may be close to fairly valued at current prices.
These estimates reflect modeled return scenarios, not guaranteed outcomes. Actual results depend on company performance, market conditions, share class, and timing.
Selling Talkiatry shares
Why shareholders consider selling
Shareholders in Talkiatry may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, Talkiatry does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.
Can you sell Talkiatry stock?
Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Healthcare & Biotech sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing Talkiatry shares would be outlined in the holder's equity agreement or the company's governing documents.
What affects the value of Talkiatry shares?
The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Healthcare & Biotech market conditions, and any recent private-market transaction activity. Data points such as the company's Series C round can help frame expectations, though they do not guarantee a transaction price.
What should holders check before selling
- The type of security held (common shares, preferred, options, RSUs)
- Whether the equity is fully vested and, for options, whether it has been exercised
- Any transfer restrictions, lock-up provisions, or company approval requirements
- Estimated net proceeds after applicable taxes and transaction fees
- Whether partial liquidity — selling a portion rather than the full position — may be a better fit
Tools for Talkiatry shareholders
Exploring equity in Talkiatry often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.
Latest funding round
Talkiatry most recently raised a Series C round in June 2024. Total funding raised to date is approximately $180M.
Lead investors in this round include Insight Partners.
Founders & company background
Talkiatry was founded in 2020 by Robert Krayn and is headquartered in New York, NY.
Investors
Industry
Similar private companies
Latest Talkiatry news
Frequently asked questions
- Is Talkiatry still a private company?
- Yes, Talkiatry is currently a private company.
- What is Talkiatry's latest funding round?
- Talkiatry's most recent known round is Series C, raised in June 2024.
- What is Talkiatry's valuation?
- Talkiatry's valuation has not been publicly disclosed.
- Who are the investors in Talkiatry?
- Notable investors include Insight Partners.
- Can I sell my Talkiatry stock?
- Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands Talkiatry stock can help you evaluate your options.
Related pages
Last verified: 2026-04-13 · Talkiatry data compiled from funding disclosures, investor announcements, corporate filings, and public records.
Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.